Hospital
Honorhealth
Honorhealth was paid $47.05M by Medicaid between Jan 2018 and Dec 2024, across 332 billing codes. Its largest line is 99285, emergency room visit (most serious) — 27% of everything it billed.
33Billing provider infoHONORHEALTH
SCOTTSDALE, AZ 85251
SCOTTSDALE, AZ 85251
33aNPI1811951429assigned 04/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$47.05M
24GClaims1,528,758
24DCodes billed332
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#12 of 78
Median peer was paid$12.21M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 239,745 | $7.01M | |
| 2019 | 241,344 | $6.95M | |
| 2020 | 197,806 | $6.11M | |
| 2021 | 224,706 | $6.78M | |
| 2022 | 223,254 | $6.80M | |
| 2023 | 237,543 | $7.32M | |
| 2024incomplete | 164,360 | $6.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 27% | 32,730 | 28,643 | $12.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 27,900 | 25,927 | $6.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 27,703 | 25,480 | $5.60M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.2% | 12,319 | 11,281 | $2.94M |
| G0378 | Hospital observation service, per hour | 6.1% | 43,777 | 16,631 | $2.88M |
| 72125 | Computed tomography, cervical spine; without contrast material | 4.6% | 5,538 | 4,996 | $2.15M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.2% | 30,151 | 21,099 | $1.98M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 27,910 | 9,143 | $1.81M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 15,398 | 14,454 | $1.68M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 4,100 | 3,768 | $961K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 14,308 | 12,603 | $946K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 1,433 | 1,345 | $812K |
320 more codes
| 70498 | 1.1% | 1,592 | $514K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 263 | $439K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,624 | $414K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 11,559 | $359K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,237 | $347K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,184 | $277K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,667 | $204K |
| 95811 | <1% | 406 | $197K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 322 | $188K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 480 | $173K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 426 | $159K |
| 59025 | Fetal non-stress test | <1% | 1,834 | $149K |
| 49083 | <1% | 393 | $143K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,409 | $127K |
| 72131 | <1% | 319 | $126K | |
| 74174 | <1% | 172 | $108K | |
| 64483 | <1% | 197 | $102K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,542 | $100K |
| 93976 | <1% | 1,315 | $100K | |
| 76801 | <1% | 561 | $94K | |
| 97161 | <1% | 6,950 | $93K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,465 | $89K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,213 | $75K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 117 | $70K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,529 | $69K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 720 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,445 | $57K |
| 47562 | <1% | 12 | $56K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 5,969 | $54K |
| 76830 | Ultrasound, transvaginal | <1% | 1,433 | $48K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 276 | $46K |
| 95806 | <1% | 500 | $45K | |
| 36430 | <1% | 482 | $37K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 717 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,430 | $36K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,840 | $34K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 298 | $32K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 119 | $31K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 11,655 | $31K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 96 | $27K |
| 70549 | <1% | 14 | $25K | |
| 97162 | <1% | 1,353 | $25K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 973 | $23K |
| 97597 | <1% | 381 | $21K | |
| 71250 | <1% | 366 | $21K | |
| 97165 | <1% | 2,087 | $20K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,657 | $19K |
| 70496 | <1% | 674 | $18K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 33,013 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 44,668 | $16K |
| 96376 | <1% | 19,455 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 40,956 | $13K |
| 93970 | <1% | 864 | $12K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 331 | $12K |
| 88341 | <1% | 267 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,840 | $11K |
| 10060 | <1% | 216 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,429 | $9K |
| 70487 | <1% | 12 | $8K | |
| 97116 | <1% | 4,447 | $8K | |
| 73630 | <1% | 1,976 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 25,094 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,328 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 44,408 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 410 | $4K |
| 73130 | <1% | 1,664 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,932 | $4K |
| 70491 | <1% | 13 | $4K | |
| 93971 | <1% | 2,218 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,399 | $4K |
| 96367 | <1% | 2,861 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,325 | $3K |
| C1729 | Catheter, drainage | <1% | 475 | $3K |
| 81001 | <1% | 33,939 | $2K | |
| 88304 | <1% | 657 | $2K | |
| 84484 | <1% | 29,969 | $2K | |
| 87040 | <1% | 8,095 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,880 | $2K |
| 12001 | <1% | 619 | $2K | |
| 70486 | <1% | 1,804 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,761 | $2K |
| 84703 | <1% | 11,734 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,804 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,332 | $1K |
| C1769 | Guide wire | <1% | 2,449 | $1K |
| 83690 | <1% | 20,025 | $1K | |
| 73030 | <1% | 2,085 | $1K | |
| 80306 | <1% | 9,382 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 33,106 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 97 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,692 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 379 | $989.26 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 16,739 | $972.65 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 901 | $953.45 |
| 82803 | <1% | 1,276 | $944.01 | |
| 81025 | <1% | 9,219 | $914.68 | |
| 85610 | <1% | 16,319 | $909.06 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,103 | $888.71 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,427 | $875.13 |
| 82248 | <1% | 15,105 | $872.62 | |
| 83605 | <1% | 10,390 | $861.50 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,993 | $822.65 |
| 97166 | <1% | 132 | $817.70 | |
| 80061 | Lipid panel | <1% | 2,839 | $806.70 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 30 | $789.94 |
| 73562 | <1% | 2,236 | $766.42 | |
| 83880 | <1% | 5,691 | $759.38 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 100 | $739.34 |
| 73590 | <1% | 848 | $721.06 | |
| 85027 | <1% | 15,944 | $698.25 | |
| 90715 | <1% | 2,911 | $696.81 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 302 | $675.92 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,412 | $675.33 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,760 | $665.46 |
| 97799 | <1% | 98 | $658.02 | |
| 83735 | <1% | 15,608 | $651.87 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,466 | $651.62 |
| J3490 | Unclassified drugs | <1% | 2,365 | $633.70 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 9,135 | $625.39 |
| 86900 | <1% | 5,369 | $620.85 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 5,547 | $606.86 |
| 73610 | <1% | 1,757 | $586.44 | |
| 85379 | <1% | 5,596 | $582.75 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,969 | $572.70 |
| 86850 | <1% | 4,722 | $517.67 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,294 | $514.96 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,010 | $511.21 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 187 | $509.52 |
| 80320 | <1% | 11,568 | $502.00 | |
| 84132 | <1% | 5,952 | $493.93 | |
| 87186 | <1% | 4,387 | $468.05 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,367 | $451.85 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,988 | $434.73 |
| 84702 | <1% | 2,212 | $426.76 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,398 | $420.38 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,235 | $401.20 |
| 82947 | <1% | 4,362 | $371.98 | |
| 73110 | <1% | 932 | $349.02 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,727 | $339.55 |
| 82962 | <1% | 39,660 | $328.55 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 4,267 | $326.27 |
| 80329 | <1% | 6,498 | $322.05 | |
| 82330 | <1% | 4,373 | $312.39 | |
| 94760 | <1% | 16,844 | $305.45 | |
| 87631 | <1% | 115 | $280.87 | |
| 80051 | <1% | 3,414 | $244.46 | |
| 87070 | <1% | 2,371 | $242.48 | |
| 82550 | <1% | 5,030 | $221.05 | |
| 87077 | <1% | 5,421 | $219.07 | |
| 85730 | <1% | 7,547 | $217.87 | |
| 73502 | <1% | 623 | $215.43 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,368 | $214.70 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 806 | $213.80 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,521 | $205.76 |
| 82607 | <1% | 863 | $204.43 | |
| 72141 | <1% | 38 | $203.88 | |
| 74018 | <1% | 1,067 | $196.51 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 434 | $193.68 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 521 | $193.08 |
| 86901 | <1% | 5,544 | $182.92 | |
| 80050 | General health panel | <1% | 150 | $178.55 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,086 | $173.94 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,133 | $169.20 |
| 82140 | <1% | 816 | $159.84 | |
| 97164 | <1% | 16 | $151.81 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 29 | $149.57 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 410 | $134.35 |
| 82150 | <1% | 1,688 | $122.79 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,129 | $119.76 |
| 0352U | <1% | 124 | $107.00 | |
| 84145 | <1% | 1,687 | $104.74 | |
| 12011 | <1% | 68 | $104.67 | |
| 84520 | <1% | 3,475 | $100.44 | |
| 80047 | <1% | 759 | $98.46 | |
| 87210 | <1% | 1,453 | $98.41 | |
| 86328 | <1% | 23 | $93.15 | |
| 80076 | <1% | 1,824 | $92.20 | |
| 87205 | <1% | 2,894 | $85.77 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,344 | $82.74 |
| 84100 | <1% | 4,930 | $74.47 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,702 | $73.65 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 736 | $69.81 |
| 87400 | <1% | 3,064 | $65.66 | |
| 86140 | <1% | 3,461 | $63.15 | |
| 82746 | <1% | 546 | $61.28 | |
| 73060 | <1% | 42 | $57.56 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 4,490 | $57.48 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,258 | $57.01 |
| 87075 | <1% | 681 | $56.84 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 728 | $56.14 |
| 96368 | <1% | 39 | $54.64 | |
| 72100 | <1% | 432 | $53.92 | |
| 88342 | <1% | 1,406 | $53.65 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,038 | $53.01 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 72 | $51.31 |
| 85014 | <1% | 2,780 | $49.63 | |
| 99152 | <1% | 1,282 | $46.65 | |
| 73080 | <1% | 190 | $45.98 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 2,626 | $43.62 |
| 73090 | <1% | 293 | $39.07 | |
| 87081 | <1% | 677 | $38.80 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,579 | $38.37 |
| 82728 | <1% | 1,246 | $36.47 | |
| 85652 | <1% | 2,307 | $28.97 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,104 | $27.86 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,351 | $26.30 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 645 | $25.02 |
| 83550 | <1% | 1,228 | $24.99 | |
| 84439 | <1% | 719 | $24.88 | |
| 90686 | <1% | 88 | $23.49 | |
| 86635 | <1% | 208 | $22.94 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,813 | $21.73 |
| 83540 | <1% | 1,251 | $20.17 | |
| 72170 | <1% | 333 | $20.16 | |
| 94770 | <1% | 620 | $19.99 | |
| 84156 | <1% | 28 | $19.66 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,487 | $19.02 |
| 83615 | <1% | 323 | $18.24 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 40 | $15.41 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,985 | $14.68 |
| 81003 | <1% | 688 | $13.99 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,448 | $13.47 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,191 | $13.36 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 759 | $12.34 |
| 15853 | <1% | 13 | $12.33 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 298 | $10.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 301 | $8.14 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,021 | $7.53 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,941 | $6.73 |
| 85007 | <1% | 1,176 | $5.70 | |
| 82270 | <1% | 247 | $5.26 | |
| 87147 | <1% | 797 | $3.62 | |
| 82565 | <1% | 183 | $3.27 | |
| 84295 | <1% | 668 | $2.81 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,403 | $2.66 |
| 82435 | <1% | 529 | $2.41 | |
| 85018 | <1% | 78 | $2.37 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,642 | $2.00 |
| A9270 | Non-covered item or service | <1% | 33,157 | $0.95 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 497 | $0.36 |
| J1815 | Injection, insulin, per 5 units | <1% | 2,918 | $0.06 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 15 | $0.00 |
| 84207 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 810 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 65 | $0.00 |
| 82010 | 0% | 312 | $0.00 | |
| 93017 | 0% | 321 | $0.00 | |
| 86923 | 0% | 108 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 26 | $0.00 |
| 84425 | 0% | 12 | $0.00 | |
| 73140 | 0% | 86 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 777 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 65 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 158 | $0.00 |
| 82375 | 0% | 186 | $0.00 | |
| 82570 | 0% | 49 | $0.00 | |
| 93356 | 0% | 161 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 982 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 96 | $0.00 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 14 | $0.00 |
| 76770 | 0% | 25 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 50 | $0.00 |
| 85347 | 0% | 140 | $0.00 | |
| 92610 | 0% | 80 | $0.00 | |
| 80202 | 0% | 60 | $0.00 | |
| 89051 | 0% | 57 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 193 | $0.00 |
| 76937 | 0% | 12 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 153 | $0.00 |
| 86709 | 0% | 41 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 94 | $0.00 |
| 29125 | 0% | 12 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 59 | $0.00 |
| 87102 | 0% | 16 | $0.00 | |
| 80074 | 0% | 12 | $0.00 | |
| 87899 | 0% | 19 | $0.00 | |
| 87045 | 0% | 15 | $0.00 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 14 | $0.00 |
| 88307 | 0% | 127 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 215 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 13 | $0.00 |
| 73120 | 0% | 19 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 60 | $0.00 |
| 82810 | 0% | 210 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 257 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 186 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 295 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 239 | $0.00 |
| 71101 | 0% | 12 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 226 | $0.00 |
| 73560 | 0% | 71 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 261 | $0.00 |
| 82553 | 0% | 83 | $0.00 | |
| 83050 | 0% | 180 | $0.00 | |
| J1921 | Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg | 0% | 17 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| 73552 | 0% | 72 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 263 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 284 | $0.00 |
| 87807 | 0% | 95 | $0.00 | |
| 94762 | 0% | 175 | $0.00 | |
| 12002 | 0% | 83 | $0.00 | |
| 29581 | 0% | 474 | $0.00 | |
| 76870 | 0% | 25 | $0.00 | |
| 86592 | 0% | 41 | $0.00 | |
| 87493 | 0% | 31 | $0.00 | |
| 87046 | 0% | 20 | $0.00 | |
| 84300 | 0% | 13 | $0.00 | |
| 92523 | 0% | 64 | $0.00 | |
| 87015 | 0% | 50 | $0.00 | |
| 77001 | 0% | 14 | $0.00 | |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 24 | $0.00 |
| 80069 | 0% | 27 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 23 | $0.00 |
| 87116 | 0% | 16 | $0.00 | |
| 87206 | 0% | 18 | $0.00 | |
| 86885 | 0% | 14 | $0.00 | |
| 85576 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDRIX, JENIFER (SENIOR NETWORK DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Honorhealth | Phoenix, AZ | $107.15M |
| Honorhealth | Phoenix, AZ | $65.78M |
| Honorhealth | Scottsdale, AZ | $23.83M |
| Honorhealth | Phoenix, AZ | $7.97M |
| Honorhealth | Scottsdale, AZ | $7.44M |
| Honorhealth | Surprise, AZ | $3.33M |
| Honorhealth | Scottsdale, AZ | $232K |
| Honorhealth | Scottsdale, AZ | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.